Real Breakthroughs
This content is for members
Bristol-Myers Squibb (BMY)
Let’s Go Shopping
In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did …
Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit
Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) Announce Global Development & Commercialization Collaboration for Nektar’s Product NKTR-214 The …
Merck’s Good News. Checkpoint Inhibitors’ Revenues
This content is for members
Last Week’s Promising News
This content is for members
Exelixis’ Exceptional Financial Results and Corporate Achievements
This content is for members
Tracing Large Pharmaceutical Companies’ Choices
This content is for members
New Breakthrough Immuno-Oncology Products
This content is for members
Prohost Letter #413
This content is for members
Some Small Outperforming Biotech Firms
This content is for members
Two Large Pharma Agreements with Halozyme in One Day. HALO Rallied
This content is for members
NewLinK Genetics: A Rally Is Recuperating NLNK’s Unwarranted Stock Losses
Indeed, updated data from the ongoing Phase 2 NLG2103 study of NewLink Genetics (NLNK) IDO inhibitor immunotherapy product indoximod in combination with the …
About Exelixis’ Transition
EXELIXIS Exelixis’ (EXEL) shareholders know well how good are the firm’s announced financial results for the second quarter of 2017. They also know well …
Prohost Letter #412 Part 3
This content is for members